2017

Июн
22

Новости фондового рынка США – NYSE, NASDAQ на 22.06.2017

Обучение торговле акциями на NYSE, Nasdaq, Amex

 

Вниз
Реакция на earnings/guidance
:

  • SCS -16.6%, ACN -3%, CACI -1.4%

Другие новости

  • ESNC -26.1% (to offer newly issued shares of common stock pursuant to an underwritten public offering)
  • KMDA -26% (withdraws Marketing Authorization Application for its proprietary inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency with the European Medicines Agency)
  • JCAP -8.4% (announces commencement of public offering of common stock)
  • WB -7.6% (vague chatter that regulators may have ordered the company to halt audio and video programming services)
  • PZRX -5% (files mixed securities shelf offering with proposed maximum aggregate offering price of $15 mln)
  • SINA -5% (in sympathy with WB)
  • SBPH -4.8% (announces proposed public offering of common stock)
  • TMHC -4.1% (prices 10 mln shares of common stock)
  • STM -3.4% (announces a $1.5 bln dual-tranche offering of New Convertible Bonds, the early redemption of its 2019 Convertible Bonds, the launch of a share buy-back program)
  • JD -1.3% (invests $397 million in Farfetch)

Комментарии аналитиков:

  • CNK -0.8% (downgraded to Underperform at Credit Suisse)

Вверх
Реакция на earnings/guidance
:

  • ORCL +11.3%, CMC +8.6%, HAIN +5.5%, CO +4.5%, APOG +4.1%

M&A news:

  • SPLS +6.8% (Sycamore Partners nearing M&A deal to purchase SPLS, according to Reuters)

Другие новости

  • TROV +13.7% (enters into agreement with a worldwide, premier biopharmaceutical company to provide Trovera urine circulating tumor DNA biomarker tests and services)
  • OVAS +8.2% (appoints Christopher Kroeger as CEO effective September 1; will restructure its organization)
  • NRZ +3.1% ( increases quarterly dividend to $0.50 per common share from $0.48 per common share)
  • NVS +2.7% (reports Phase 3 data for ACZ885 demonstrating reduction in cardiovascular risk)
  • SHPG +2.3% (receives EMA Validation of Veyvondi)
  • FGEN +1% (confirms receipt of Orphan Drug Designation by the FDA for Pamrevlumab)

Комментарии аналитиков:

  • ATVI +1.3% (target raised to $70 from $60 at Oppenheimer)
  • VLO +1.2% (upgraded to Buy from Hold at Jefferies)

Сканер Акций :

52H$winnerUP$ loser
ADBE
SWK
JNJ
VRTX
CELG
PEP
RHT
ABC
CLVS
Q
ED
ALNY
CNC
XLV
XBI
RMD
AEP
CTSH
OC
LABU
CCL
LUV
BAX
BIB
Z
GRUB
XL
BLL
ARMK
CTLT
INCY
RHT
VRTX
LABU
BLUE
CELG
ESPR
BMRN
LZB
CLVS
AVXS
BABA
ALXN
CA
BIB
TSRO
WGO
XBI
SINA
ADBE
WDAY
DWT
ALNY
TQQQ
SYNA
WB
WDC
SCO
NOW
ABC
CLVS
LABU
INCY
CELG
VRTX
ALNY
RHT
BLUE
WFM
BMRN
DWT
BIB
BABA
SINA
ADBE
XBI
SHOP
SYNA
ALXN
SCO
ESPR
WB
AVXS
CE
WGO
CA
LZB
PRXL
WDAY
BIVV
PLCE
PAM
BURL
CAT
AAP
JDST
SIG
DOV
BMA
ITW
PDCE
ACIA
PRU
FL
KMT
CFX
EGN
CJ
GGAL
URI
DNKN
DD
APA
LNC
SPGI
CVX
ECL
FLS
PM
EMN

Трансляция сделок Day Trading на NYSE NASDAQ

Комментарии

Группа Вконтакте

Партнеры

Облако тегов

Меню: